Chongqing Claruvis Pharmaceutical Co., Ltd.
6 clinical trials · Sponsor
◉ Watch Chongqing Claruvis Pharmaceutical Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines (NCT06481475) | Chongqing Claruvis Pharmaceutical Co., Ltd. | 2025-01-09 |
| A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults (NCT06783114) | Chongqing Claruvis Pharmaceutical Co., Ltd. | 2024-09-14 |
| A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines (NCT06583486) | Chongqing Claruvis Pharmaceutical Co., Ltd. | 2024-03-19 |
| A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines (NCT05743634) | Chongqing Claruvis Pharmaceutical Co., Ltd. | 2022-03-22 |
Track Chongqing Claruvis Pharmaceutical Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.